THERALASE TECHNOLOGIES INC (TLT.CA) Stock Fundamental Analysis
Canada - TSX-V:TLT - CA88337V1004 - Common Stock
0.21 CAD
+0.01 (+5%)
Overall TLT gets a fundamental rating of 3 out of 10. We evaluated TLT against 15 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TLT have multiple concerns. TLT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TLT has reported negative net income.
In the past year TLT has reported a negative cash flow from operations.
TLT had negative earnings in each of the past 5 years.
In the past 5 years TLT always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -141.86%, TLT perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
TLT's Return On Equity of -335.23% is in line compared to the rest of the industry. TLT outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -141.86% | ||
| ROE | -335.23% | ||
| ROIC | N/A |
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 55.81%, TLT is in line with its industry, outperforming 53.33% of the companies in the same industry.
TLT's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
2. Health
2.1 Basic Checks
TLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TLT has been increased compared to 5 years ago.
Compared to 1 year ago, TLT has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -17.27, we must say that TLT is in the distress zone and has some risk of bankruptcy.
TLT has a Altman-Z score (-17.27) which is comparable to the rest of the industry.
TLT has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TLT (0.13) is better than 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.27 |
ROIC/WACCN/A
WACC7.84%
2.3 Liquidity
A Current Ratio of 0.96 indicates that TLT may have some problems paying its short term obligations.
The Current ratio of TLT (0.96) is better than 66.67% of its industry peers.
TLT has a Quick Ratio of 0.96. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a decent Quick ratio value of 0.62, TLT is doing good in the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.62 |
3. Growth
3.1 Past
TLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
The Revenue has grown by 16.00% in the past year. This is quite good.
TLT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.40% yearly.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)16%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%117.89%
3.2 Future
The Earnings Per Share is expected to grow by 37.61% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 256.32% on average over the next years. This is a very strong growth
EPS Next Y39.41%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLT. In the last year negative earnings were reported.
Also next year TLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TLT's earnings are expected to grow with 37.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
5. Dividend
5.1 Amount
No dividends for TLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:TLT (11/14/2025, 7:00:00 PM)
0.21
+0.01 (+5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners2.83%
Ins Owner ChangeN/A
Market Cap52.03M
Revenue(TTM)1.07M
Net Income(TTM)-4.28M
Analysts84.44
Price Target0.71 (238.1%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.63%
Min EPS beat(2)-94.17%
Max EPS beat(2)2.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-24.53%
Min Revenue beat(2)-55.73%
Max Revenue beat(2)6.67%
Revenue beat(4)3
Avg Revenue beat(4)88.3%
Min Revenue beat(4)-55.73%
Max Revenue beat(4)236.89%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40%
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 48.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 40.77 | ||
| P/tB | 40.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -141.86% | ||
| ROE | -335.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.81% | ||
| FCFM | N/A |
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
F-Score4
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 34.64% | ||
| Cap/Sales | 8.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | -17.27 |
F-Score4
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)14.29%
Cap/Depr(5y)27.96%
Cap/Sales(3y)3.87%
Cap/Sales(5y)8.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y39.41%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue 1Y (TTM)16%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%117.89%
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A
EBIT growth 1Y2.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.52%
OCF growth 3YN/A
OCF growth 5YN/A
THERALASE TECHNOLOGIES INC / TLT.CA FAQ
What is the ChartMill fundamental rating of THERALASE TECHNOLOGIES INC (TLT.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TLT.CA.
What is the valuation status of THERALASE TECHNOLOGIES INC (TLT.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to THERALASE TECHNOLOGIES INC (TLT.CA). This can be considered as Overvalued.
How profitable is THERALASE TECHNOLOGIES INC (TLT.CA) stock?
THERALASE TECHNOLOGIES INC (TLT.CA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for THERALASE TECHNOLOGIES INC?
The Earnings per Share (EPS) of THERALASE TECHNOLOGIES INC (TLT.CA) is expected to grow by 39.41% in the next year.